We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.7%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$50.8M
Cap. Flow
+$91.6M
Cap. Flow %
8.41%
Top 10 Hldgs %
59.85%
Holding
90
New
23
Increased
22
Reduced
6
Closed
21

Top Buys

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$43.7M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$34.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$12.1M
5
XLRN
Acceleron Pharma
XLRN
+$9.98M

Top Sells

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$13.5M
2
AZN icon
AstraZeneca
AZN
+$10.6M
3
ANAB icon
AnaptysBio
ANAB
+$7.16M
4
XNCR icon
Xencor
XNCR
+$6.52M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.43M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
26
MacroGenics
MGNX
$235M
$9.34M 0.86%
550,443
+26,687
+5% +$458K
VRTX icon
27
Vertex Pharmaceuticals
VRTX
$121B
$9.22M 0.85%
+50,301
New +$8.79M
AMGN icon
28
PUT
Amgen
AMGN
$203B
$9.21M 0.85%
+50,000
New +$8.95M
AGN
29
CALL
DELISTED
Allergan plc
AGN
$8.37M 0.77%
+50,000
New +$6.92M
BMY icon
30
Bristol-Myers Squibb
BMY
$127B
$7.88M 0.72%
+173,849
New +$8.1M
ETTX
31
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$7.61M 0.7%
1,180,178
– –
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$7.28M 0.67%
583,309
-799
-0.1% -$10.1K
BMRN icon
33
BioMarin Pharmaceuticals
BMRN
$11.5B
$7.27M 0.67%
84,896
+66,402
+359% +$5.68M
DERM
34
DELISTED
Dermira, Inc.
DERM
$6.31M 0.58%
659,882
+176,242
+36% +$1.9M
INCY icon
35
Incyte
INCY
$23.5B
$5.91M 0.54%
69,612
+16,515
+31% +$1.33M
SYBX
36
DELISTED
Synlogic
SYBX
$5.23M 0.48%
38,331
– –
ORTX
37
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.11M 0.47%
36,547
+8,939
+32% +$1.57M
KDMN
38
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.54M 0.42%
2,204,202
+532,432
+32% +$1.19M
BMY icon
39
CALL
Bristol-Myers Squibb
BMY
$127B
$4.53M 0.42%
+100,000
New +$4.66M
ACRS icon
40
Aclaris Therapeutics
ACRS
$730M
$4.19M 0.38%
1,911,573
– –
ACAD icon
41
Acadia Pharmaceuticals
ACAD
$4.25B
$4.16M 0.38%
+155,576
New +$3.97M
ZYME icon
42
Zymeworks
ZYME
$1.68B
$4.14M 0.38%
+188,057
New +$3.45M
AKBA icon
43
Akebia Therapeutics
AKBA
$327M
$4.11M 0.38%
848,356
+331,595
+64% +$1.89M
QURE icon
44
CALL
uniQure
QURE
$2.68B
$3.91M 0.36%
+50,000
New +$3.19M
OTIC
45
DELISTED
Otonomy, Inc.
OTIC
$3.68M 0.34%
1,337,568
+313,703
+31% +$836K
ARQL
46
DELISTED
Arqule Inc
ARQL
$3.1M 0.29%
281,857
-73,868
-21% -$514K
FOMX
47
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.65M 0.24%
1,115,810
+283,517
+34% +$847K
XBIT icon
48
XBiotech
XBIT
$69.2M
$2.52M 0.23%
331,811
+70,420
+27% +$612K
ZGNX
49
CALL
DELISTED
Zogenix, Inc.
ZGNX
$2.39M 0.22%
+50,000
New +$2.01M
ITCI
50
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.27M 0.21%
+175,000
New +$2.24M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2019 Portfolio in Review

As of Q2 2019, Sofinnova Investments held 90 positions worth $1.09B, up 4.9% from $1.04B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $91.6M of net new capital in Q2 2019, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was NextCure: 210,155 shares worth $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Coherus Oncology, an estimated $13.5M trimmed.

  • Sofinnova Investments's largest Q2 2019 buy was NextCure: 210,155 shares worth $37.8M.
  • Sofinnova Investments added most to Ascendis Pharma A/S in Q2 2019, an estimated $12.1M increase.
  • Sofinnova Investments's biggest Q2 2019 reduction was Coherus Oncology, cutting an estimated $13.5M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2019, selling an estimated $10.6M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.09B portfolio in Q2 2019.
  • Sofinnova Investments opened 23 new positions and closed 21 in Q2 2019.
  • Sofinnova Investments's portfolio value rose 4.9% quarter-over-quarter to $1.09B.

Based on Sofinnova Investments's 13F filing for Q2 2019, filed 13 Aug 2019.